Showing results (201-210 of 277) with videos related to

Sort By:
Pageof 28
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian CancerFlorian Heitz, Stefan Kommoss, Roshan Tourani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 ConsortiumNicole Concin, Ioana Braicu, Pierre Combe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian CancerJoyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
Clinical trials in recurrent ovarian cancerMichael Friedlander, Edward Trimble, Anna Tinker, et al.
BMC Medical Ethics|October 23, 2016
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 studyDavid J Pulford, Philipp Harter, Anne Floquet, et al.
The New England Journal of Medicine|February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian NeoplasmsPhilipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
The Lancet. Oncology|August 31, 2024
Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGEPhilippe Morice, Giovanni Scambia, Nadeem R Abu-Rustum, et al.
The Lancet. Oncology|November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trialAndreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
Pageof 28